Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 52.3% in May

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,060,180 shares, a drop of 52.3% from the April 30th total of 8,509,923 shares. Based on an average trading volume of 3,052,240 shares, the days-to-cover ratio is currently 1.3 days. Currently, 12.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $1.00.

Institutional Trading of Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP bought a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.17% of the company’s stock.

Theriva Biologics Price Performance

TOVX traded down $0.00 during midday trading on Monday, reaching $0.28. 1,495,708 shares of the company’s stock were exchanged, compared to its average volume of 16,817,598. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 1.63. Theriva Biologics has a 1-year low of $0.16 and a 1-year high of $0.86. The stock has a market capitalization of $9.51 million, a PE ratio of -0.01 and a beta of 1.11. The business’s 50-day moving average price is $0.29 and its 200 day moving average price is $0.24.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.05) earnings per share for the quarter.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.